Literature DB >> 17038533

Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).

Elihu Estey1, Marcos de Lima, Raoul Tibes, Sherry Pierce, Hagop Kantarjian, Richard Champlin, Sergio Giralt.   

Abstract

To prospectively assess the applicability of reduced-intensity conditioning hematopoietic stem cell transplantation (RIC-HSCT), we wrote a protocol in which all untreated patients 50 years or older with acute myeloid leukemia (AML) and unfavorable cytogenetics would be evaluated during induction for a possible RIC-HSCT in first complete remission (CR1). Ninety-nine of 259 patients entered CR. Fifty-three of the 99 were seen by the Transplant Service with the remainder not seen because of illness, lack/unavailability of siblings, refusal, or, primarily, unclear reasons (21 patients). A donor was identified for 26 patients (21 sibling, 5 unrelated) with RIC-HSCT performed in 14 (13 sibling). Results in consulted patients suggested that 50% or fewer of the 85 patients who did not undergo transplantation were potential transplant candidates. We attempted to find one or more chemotherapy pair-mates for each patient who underwent transplantation based on cytogenetics, age, and a relapse-free survival (RFS) time that was more than or equal to the time from CR1 to RIC-HSCT in the patient who underwent transplantation. Thirty-two of the 39 matches favored (longer RFS) RIC-HSCT and 7, chemotherapy. The probability that the corresponding beta distribution was different than expected (ie, that RIC-HSCT was superior) was 0.99 (P=.004). Results were similar with respect to survival. While RIC-HSCT thus seems of interest, methods are needed to extend its applicability.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17038533     DOI: 10.1182/blood-2006-05-021907

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  81 in total

Review 1.  Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma.

Authors:  Koen van Besien
Journal:  Curr Opin Oncol       Date:  2011-11       Impact factor: 3.645

2.  Survival for older patients with acute myeloid leukemia: a population-based study.

Authors:  Betul Oran; Daniel J Weisdorf
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

Review 3.  Molecular therapy for acute myeloid leukaemia.

Authors:  Catherine C Coombs; Martin S Tallman; Ross L Levine
Journal:  Nat Rev Clin Oncol       Date:  2015-12-01       Impact factor: 66.675

4.  Reduced-intensity allogeneic hematopoietic transplantation should be considered a standard of care for older patients with acute myeloid leukemia.

Authors:  Richard Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-17       Impact factor: 5.742

5.  Treatment of acute myeloid leukemia.

Authors:  Elihu H Estey
Journal:  Haematologica       Date:  2009-01       Impact factor: 9.941

6.  Quality of life and outcomes in patients⩾60 years of age after allogeneic hematopoietic cell transplantation.

Authors:  B K Hamilton; L Rybicki; J Dabney; L McLellan; H Haddad; L Foster; D Abounader; M Kalaycio; R Sobecks; R Dean; H Duong; B T Hill; B J Bolwell; E A Copelan
Journal:  Bone Marrow Transplant       Date:  2014-07-28       Impact factor: 5.483

7.  Treatment of acute myeloid leukemia in the elderly.

Authors:  Elihu H Estey
Journal:  Haematologica       Date:  2011-06       Impact factor: 9.941

Review 8.  Upfront therapy of acute myeloid leukemia.

Authors:  Jenna Vanliere Canzoniero; Bhavana Bhatnagar; Maria R Baer; Ivana Gojo
Journal:  Curr Oncol Rep       Date:  2011-10       Impact factor: 5.075

Review 9.  [Individualized management and therapy of myelodysplastic syndromes].

Authors:  Reinhard Stauder; Friedrich Wimazal; Thomas Nösslinger; Otto Krieger; Wolfgang R Sperr; Heinz Sill; Michael Pfeilstöcker; Peter Valent
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

Review 10.  Last marrow standing: bone marrow transplantation for acquired bone marrow failure conditions.

Authors:  Aaron T Gerds; Bart L Scott
Journal:  Curr Hematol Malig Rep       Date:  2012-12       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.